Notably, the immunosuppressive role of FAM174B parallels that of established therapeutic targets such as FGFR and PPARG, suggesting potential benefits from combination therapies targeting these pathways in FAM174B-high BLCA. This evidence concerns the gene PPARG and bladder transitional cell carcinoma.